Systemic Anti-Cancer Therapy Regimen Library New Zealand Formulary

Leukaemias Regimens

Haematology regimens within the SACT Regimen Library currently only specify mandatory supportive care medicines to be used for all patients, unless contraindicated. A clinically equivalent mandatory medicine may be substituted as per institutional practice.

Supportive care factors are included in all regimens, with the appropriate dimensions (value) as Recommended (for most patients), Consider (for some patients after clinical risk assessment), or with guidance (e.g. emetogenicity classification or if variable). Centres are expected to include antiemetics and other supportive care medicines within their own prescribing systems.

Acute lymphoblastic Regimens

Published Sort regimens by
LEU ALL precursor B-cell - blinatumomab [CNS1 and CNS2] Id: 312041000210100 Published date: Version: 1.0.0
312041000210100
1.0.0
18/03/2024
LEU ALL precursor B-cell - blinatumomab [CNS3] Id: 312031000210108 Published date: Version: 1.0.0
312031000210108
1.0.0
18/03/2024
LEU ALL precursor B-cell Relapsed/Refractory - inotuzumab ozogamicin Id: 506411000210108 Published date: Version: 1.0.0
Components ▾
Cycle 1, and subsequent cycles for patients who achieved CR or CRi Id: 506421000210103 Published date: Version: 0.0.16
Cycle 1, and subsequent cycles for patients who do not achieve CR or CRi Id: 506431000210101 Published date: Version: 0.0.21
506411000210108
1.0.0
06/05/2025

AALL1131 Regimens

Published Sort regimens by
LEU ALL precursor B-cell - AALL1131 [very high risk] Id: 392831000210102 Published date: Version: 2.0.0
Components ▾
AALL1131 [very high risk] - Induction for CNS 1+ Id: 392841000210105 Published date: Version: 0.0.9
AALL1131 [very high risk] - Induction for CNS 2+ Id: 392851000210108 Published date: Version: 0.0.7
AALL1131 [very high risk] - Induction for CNS 3+ Id: 392861000210106 Published date: Version: 0.0.6
AALL1131 [very high risk] - Consolidation for CNS 1/2+ Id: 392871000210100 Published date: Version: 0.0.11
AALL1131 [very high risk] - Consolidation for CNS 3+ Id: 392881000210103 Published date: Version: 0.0.10
AALL1131 [very high risk] - Interim maintenance 1 Id: 392891000210101 Published date: Version: 0.0.16
AALL1131 [very high risk] - Delayed intensification Id: 392901000210100 Published date: Version: 0.0.13
AALL1131 [very high risk] - Interim maintenance 2 Id: 392911000210103 Published date: Version: 0.0.9
AALL1131 [very high risk] - Maintenance for CNS 1/2+ Id: 392921000210108 Published date: Version: 0.0.10
AALL1131 [very high risk] - Maintenance for CNS 3+ Id: 392931000210105 Published date: Version: 0.0.10
392831000210102
2.0.0
03/04/2025
LEU ALL precursor B-cell BCR-ABL1+ - modified AALL1131 with daSATinib Id: 497271000210108 Published date: Version: 1.0.0
Components ▾
mAALL1131 with daSATinib - Induction for CNS 1+ Id: 497281000210105 Published date: Version: 0.0.14
mAALL1131 with daSATinib - Induction for CNS 2+ Id: 497291000210107 Published date: Version: 0.0.14
mAALL1131 with daSATinib - Induction for CNS 3+ Id: 497301000210106 Published date: Version: 0.0.12
mAALL1131 with daSATinib - Consolidation for CNS 1/2+ Id: 497311000210108 Published date: Version: 0.0.21
mAALL1131 with daSATinib - Consolidation for CNS 3+ Id: 497321000210103 Published date: Version: 0.0.17
mAALL1131 with daSATinib - Interim maintenance 1 Id: 497331000210101 Published date: Version: 0.0.8
mAALL1131 with daSATinib - Delayed intensification Id: 497341000210109 Published date: Version: 0.0.23
mAALL1131 with daSATinib - Interim maintenance 2 Id: 497351000210107 Published date: Version: 0.0.12
mAALL1131 with daSATinib - Maintenance for CNS 1/2+ Id: 497361000210105 Published date: Version: 0.0.16
mAALL1131 with daSATinib - Maintenance for CNS 3+ Id: 497371000210104 Published date: Version: 0.0.15
497271000210108
1.0.0
23/03/2025
LEU ALL precursor B-cell BCR-ABL1+ - modified AALL1131 with imatinib Id: 506141000210101 Published date: Version: 1.0.0
Components ▾
mAALL1131 with imatinib - Induction for CNS1+ Id: 506151000210103 Published date: Version: 0.0.34
mAALL1131 with imatinib - Induction for CNS2+ Id: 506161000210100 Published date: Version: 0.0.28
mAALL1131 with imatinib - Induction for CNS3+ Id: 506171000210106 Published date: Version: 0.0.23
mAALL1131 with imatinib - Consolidation for CNS1/2+ Id: 506181000210108 Published date: Version: 0.0.35
mAALL1131 with imatinib - Consolidation for CNS3+ Id: 506191000210105 Published date: Version: 0.0.14
mAALL1131 with imatinib - Interim maintenance 1 Id: 506201000210107 Published date: Version: 0.0.33
mAALL1131 with imatinib - Delayed intensification Id: 506211000210109 Published date: Version: 0.0.28
mAALL1131 with imatinib - Interim maintenance 2 Id: 506221000210104 Published date: Version: 0.0.31
mAALL1131 with imatinib - Maintenance for CNS 1/2+ Id: 506231000210102 Published date: Version: 0.0.30
mAALL1131 with imatinib - Maintenance for CNS 3+ Id: 506241000210105 Published date: Version: 0.0.21
506141000210101
1.0.0
23/03/2025

GMALL Regimens

Published Sort regimens by
LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [55 years and under] Id: 392561000210108 Published date: Version: 1.0.0
Components ▾
GMALL T-LBL 1/2004 [55 years and under] - Pre-phase and Induction I and II Id: 392571000210102 Published date: Version: 0.0.13
GMALL T-LBL 1/2004 [55 years and under] - Consolidation I Id: 392581000210100 Published date: Version: 0.0.12
GMALL T-LBL 1/2004 [55 years and under] - HDMTX/ASP Id: 392591000210103 Published date: Version: 0.0.10
GMALL T-LBL 1/2004 [55 years and under] - Reinduction I and II Id: 392521000210101 Published date: Version: 0.0.11
GMALL T-LBL 1/2004 [55 years and under] - VM26/ARAC Id: 392531000210104 Published date: Version: 0.0.5
GMALL T-LBL 1/2004 [55 years and under] - CYCLO/ARAC Id: 392541000210107 Published date: Version: 0.0.6
GMALL T-LBL 1/2004 [55 years and under] - Intrathecal Triple Prophylaxis Id: 392551000210105 Published date: Version: 0.0.7
392561000210108
1.0.0
20/05/2024
LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [over 55 years] Id: 392481000210101 Published date: Version: 1.0.0
Components ▾
GMALL T-LBL 1/2004 [over 55 years] - Pre-phase and Induction I and II Id: 392491000210104 Published date: Version: 0.0.4
GMALL T-LBL 1/2004 [over 55 years] - Consolidation I Id: 392501000210109 Published date: Version: 0.0.4
GMALL T-LBL 1/2004 [over 55 years] - HDMTX/ASP Id: 392511000210106 Published date: Version: 0.0.2
GMALL T-LBL 1/2004 [over 55 years] - Reinduction I and II Id: 392521000210101 Published date: Version: 0.0.11
GMALL T-LBL 1/2004 [over 55 years] - VM26/ARAC Id: 392531000210104 Published date: Version: 0.0.5
GMALL T-LBL 1/2004 [over 55 years] - CYCLO/ARAC Id: 392541000210107 Published date: Version: 0.0.6
GMALL T-LBL 1/2004 [over 55 years] - Intrathecal Triple Prophylaxis Id: 392551000210105 Published date: Version: 0.0.7
392481000210101
1.0.0
20/05/2024

HyperCVAD Regimens

Published Sort regimens by
LEU ALL - HyperCVAD Part A and B followed by POMP Maintenance [60 years and under] Id: 312321000210108 Published date: Version: 1.0.0
Components ▾
HyperCVAD [60 years and under] - Part A with CNS prophylaxis for Unknown Risk [default] Id: 312331000210105 Published date: Version: 0.0.31
HyperCVAD [60 years and under] - Part A with CNS prophylaxis for High Risk Id: 312341000210102 Published date: Version: 0.0.10
HyperCVAD [60 years and under] - Part B with CNS prophylaxis for Unknown Risk [default] Id: 312351000210104 Published date: Version: 0.0.28
HyperCVAD [60 years and under] - Part B with CNS prophylaxis for High Risk Id: 312361000210101 Published date: Version: 0.0.14
POMP Maintenance Id: 312311000210103 Published date: Version: 0.0.13
312321000210108
1.0.0
02/04/2024
LEU ALL - HyperCVAD Part A and B followed by POMP Maintenance [over 60 years] Id: 312261000210109 Published date: Version: 1.0.0
Components ▾
HyperCVAD [over 60 years] - Part A with CNS prophylaxis for Unknown Risk [default] Id: 312271000210103 Published date: Version: 0.0.3
HyperCVAD [over 60 years] - Part A with CNS prophylaxis for High Risk Id: 312281000210101 Published date: Version: 0.0.2
HyperCVAD [over 60 years] - Part B with CNS prophylaxis for Unknown risk [default] Id: 312291000210104 Published date: Version: 0.0.13
HyperCVAD [over 60 years] - Part B with CNS prophylaxis for High Risk Id: 312301000210100 Published date: Version: 0.0.7
POMP Maintenance Id: 312311000210103 Published date: Version: 0.0.13
312261000210109
1.0.0
02/04/2024
LEU ALL - HyperCVAD with pegaspargase Part A and B followed by POMP Maintenance [under 40 years] Id: 392431000210100 Published date: Version: 1.0.0
Components ▾
HyperCVAD with pegaspargase [under 40 years] - Part A with CNS prophylaxis for Unknown Risk [default] Id: 392441000210108 Published date: Version: 0.0.3
HyperCVAD with pegaspargase [under 40 years] - Part A with CNS prophylaxis for High Risk Id: 392451000210106 Published date: Version: 0.0.3
HyperCVAD with pegaspargase [under 40 years] - Part B with CNS prophylaxis for Unknown Risk [default] Id: 392461000210109 Published date: Version: 0.0.11
HyperCVAD with pegaspargase [under 40 years] - Part B with CNS prophylaxis for High Risk Id: 392471000210103 Published date: Version: 0.0.3
POMP Maintenance Id: 312311000210103 Published date: Version: 0.0.13
392431000210100
1.0.0
20/05/2024
LEU ALL precursor B-cell BCR-ABL1+ - HyperCVAD with daSATinib Part A and B followed by Maintenance [60 years and under] Id: 392681000210104 Published date: Version: 1.0.0
Components ▾
HyperCVAD with daSATinib [60 years and under] - Part A with CNS prophylaxis for Unknown Risk [default] Id: 392631000210103 Published date: Version: 0.0.15
HyperCVAD with daSATinib [60 years and under] - Part A with CNS prophylaxis for High Risk Id: 392641000210106 Published date: Version: 0.0.8
HyperCVAD with daSATinib [60 years and under] - Part B with CNS prophylaxis for Unknown Risk [default] Id: 392691000210102 Published date: Version: 0.0.14
HyperCVAD with daSATinib [60 years and under] - Part B with CNS prophylaxis for High Risk Id: 392701000210102 Published date: Version: 0.0.16
HyperCVAD with daSATinib maintenance Id: 392671000210101 Published date: Version: 0.0.19
392681000210104
1.0.0
10/06/2024
LEU ALL precursor B-cell BCR-ABL1+ - HyperCVAD with daSATinib Part A and B followed by Maintenance [over 60 years] Id: 392621000210100 Published date: Version: 1.0.0
Components ▾
HyperCVAD with daSATinib [over 60 years] - Part A with CNS prophylaxis for Unknown Risk [default] Id: 392631000210103 Published date: Version: 0.0.15
HyperCVAD with daSATinib [over 60 years] - Part A with CNS prophylaxis for High Risk Id: 392641000210106 Published date: Version: 0.0.8
HyperCVAD with daSATinib [over 60 years] - Part B with CNS prophylaxis for Unknown Risk [default] Id: 392651000210109 Published date: Version: 0.0.10
HyperCVAD with daSATinib [over 60 years] - Part B with CNS prophylaxis for High Risk Id: 392661000210107 Published date: Version: 0.0.9
HyperCVAD with daSATinib maintenance Id: 392671000210101 Published date: Version: 0.0.19
392621000210100
1.0.0
10/06/2024
LEU ALL precursor B-cell BCR-ABL1+ - HyperCVAD with RITUximab and daSATinib Part A and B followed by Maintenance [60 years and under] Id: 392711000210100 Published date: Version: 1.0.0
Components ▾
HyperCVAD with RITUximab and daSATinib [60 years and under] - Part A with CNS prophylaxis for Unknown Risk [default] Id: 392721000210105 Published date: Version: 0.0.22
HyperCVAD with RITUximab and daSATinib [60 years and under] - Part A with CNS prophylaxis for High Risk Id: 392731000210107 Published date: Version: 0.0.16
HyperCVAD with RITUximab and daSATinib [60 years and under] - Part B with CNS prophylaxis for Unknown Risk [default] Id: 392741000210104 Published date: Version: 0.0.39
HyperCVAD with RITUximab and daSATinib [60 years and under] - Part B with CNS prophylaxis for High Risk Id: 392751000210101 Published date: Version: 0.0.22
Maintenance with daSATinib Id: 392671000210101 Published date: Version: 0.0.19
392711000210100
1.0.0
10/06/2024
LEU ALL precursor B-cell BCR-ABL1+ - HyperCVAD with RITUximab and daSATinib Part A and B followed by Maintenance [over 60 years] Id: 392761000210103 Published date: Version: 1.0.0
Components ▾
HyperCVAD with RITUximab and daSATinib [over 60 years] - Part A with CNS prophylaxis for Unknown Risk [default] Id: 392721000210105 Published date: Version: 0.0.22
HyperCVAD with RITUximab and daSATinib [over 60 years] - Part A with CNS prophylaxis for High Risk Id: 392731000210107 Published date: Version: 0.0.16
HyperCVAD with RITUximab and daSATinib [over 60 years] - Part B with CNS prophylaxis for Unknown Risk [default] Id: 392771000210109 Published date: Version: 0.0.26
HyperCVAD with RITUximab and daSATinib [over 60 years] - Part B with CNS prophylaxis for High Risk Id: 392811000210109 Published date: Version: 0.0.19
Maintenance with daSATinib Id: 392671000210101 Published date: Version: 0.0.19
392761000210103
1.0.0
10/06/2024
LEU ALL precursor B-cell - HyperCVAD with RITUximab and pegaspargase Part A and B followed by POMP Maintenance [under 40 years] Id: 506471000210104 Published date: Version: 1.0.0
Components ▾
HyperCVAD with RITUximab and pegaspargase [under 40 years] - Part A with CNS prophylaxis for Unknown Risk [default] Id: 506481000210102 Published date: Version: 0.0.11
HyperCVAD with RITUximab and pegaspargase [under 40 years] - Part A with CNS prophylaxis for High Risk Id: 506491000210100 Published date: Version: 0.0.9
HyperCVAD with RITUximab and pegaspargase [under 40 years] - Part B with CNS prophylaxis for Unknown Risk [default] Id: 506501000210105 Published date: Version: 0.0.10
HyperCVAD with RITUximab and pegaspargase [under 40 years] - Part B with CNS prophylaxis for High Risk Id: 506511000210107 Published date: Version: 0.0.9
POMP Maintenance Id: 312311000210103 Published date: Version: 0.0.13
506471000210104
1.0.0
24/06/2025
LEU ALL precursor B-cell - HyperCVAD with RITUximab Part A and B followed by POMP Maintenance [60 years and under] Id: 392301000210101 Published date: Version: 1.0.0
Components ▾
HyperCVAD with RITUximab [60 years and under] - Part A with CNS prophylaxis for Unknown Risk [default] Id: 392311000210104 Published date: Version: 0.0.19
HyperCVAD with RITUximab [60 years and under] - Part A with CNS prophylaxis for High risk Id: 392321000210109 Published date: Version: 0.0.12
HyperCVAD with RITUximab [60 years and under] - Part B with CNS prophylaxis for Unknown Risk [default] Id: 392331000210106 Published date: Version: 0.0.25
HyperCVAD with RITUximab [60 years and under] - Part B with CNS prophylaxis for High Risk Id: 392341000210103 Published date: Version: 0.0.13
POMP Maintenance Id: 312311000210103 Published date: Version: 0.0.13
392301000210101
1.0.0
13/05/2024
LEU ALL precursor B-cell - HyperCVAD with RITUximab Part A and B followed by POMP Maintenance [over 60 years] Id: 391921000210100 Published date: Version: 1.0.0
Components ▾
HyperCVAD with RITUximab [over 60 years] - Part A with CNS prophylaxis for Unknown Risk [default] Id: 391931000210103 Published date: Version: 0.0.2
HyperCVAD with RITUximab [over 60 years] - Part A with CNS prophylaxis for High Risk Id: 391941000210106 Published date: Version: 0.0.3
HyperCVAD with RITUximab [over 60 years] - Part B with CNS prophylaxis for Unknown Risk [default] Id: 392281000210102 Published date: Version: 0.0.17
HyperCVAD with RITUximab [over 60 years] - Part B with CNS prophylaxis for High Risk Id: 392291000210100 Published date: Version: 0.0.11
POMP Maintenance Id: 312311000210103 Published date: Version: 0.0.13
391921000210100
1.0.0
13/05/2024

UKALL14 Regimens

Published Sort regimens by
LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with daSATinib Id: 311471000210109 Published date: Version: 1.0.0
Components ▾
Steroid pre-phase Id: 311231000210106 Published date: Version: 0.0.5
UKALL14 with daSATinib - Phase 1 Induction Id: 311481000210106 Published date: Version: 0.0.2
UKALL14 with daSATinib - Phase 2 Induction Id: 311491000210108 Published date: Version: 0.0.3
UKALL14 with daSATinib - Intensification/CNS prophylaxis Id: 311501000210103 Published date: Version: 0.0.10
UKALL14 with daSATinib - Consolidation [Cycles 1 and 2] Id: 311511000210101 Published date: Version: 0.0.1
UKALL14 with daSATinib - Consolidation/delayed intensification [Cycle 3] Id: 311521000210106 Published date: Version: 0.0.5
UKALL14 with daSATinib - Consolidation [Cycle 4] Id: 311531000210108 Published date: Version: 0.0.2
UKALL14 with daSATinib - Maintenance Id: 311541000210100 Published date: Version: 0.0.7
311471000210109
1.0.0
15/01/2024
LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with RITUximab and daSATinib [for transplant] Id: 311221000210109 Published date: Version: 1.0.0
Components ▾
Steroid pre-phase Id: 311231000210106 Published date: Version: 0.0.5
UKALL14 with RITUximab and daSATinib [for transplant] - Phase 1 Induction Id: 311241000210103 Published date: Version: 0.0.20
UKALL14 with RITUximab and daSATinib [for transplant] - Phase 2 Induction Id: 311251000210100 Published date: Version: 0.0.22
UKALL14 with RITUximab and daSATinib [for transplant] - Intensification/CNS prophylaxis Id: 311261000210102 Published date: Version: 0.0.8
UKALL14 with RITUximab and daSATinib [for transplant] - Consolidation [Cycles 1 and 2] Id: 311271000210108 Published date: Version: 0.0.23
UKALL14 with RITUximab and daSATinib [for transplant] - Consolidation/delayed intensification [Cycle 3] Id: 311281000210105 Published date: Version: 0.0.30
UKALL14 with RITUximab and daSATinib [for transplant] - Consolidation [Cycle 4] Id: 311291000210107 Published date: Version: 0.0.21
311221000210109
1.0.0
07/12/2023
LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with RITUximab and daSATinib [not for transplant] Id: 311421000210105 Published date: Version: 1.0.0
Components ▾
Steroid pre-phase Id: 311231000210106 Published date: Version: 0.0.5
UKALL14 with RITUximab and daSATinib [not for transplant] - Phase 1 Induction Id: 311241000210103 Published date: Version: 0.0.20
UKALL14 with RITUximab and daSATinib [not for transplant] - Phase 2 Induction Id: 311431000210107 Published date: Version: 0.0.3
UKALL14 with RITUximab and daSATinib [not for transplant] - Intensification/CNS prophylaxis Id: 311441000210104 Published date: Version: 0.0.36
UKALL14 with RITUximab and daSATinib [not for transplant] - Consolidation [Cycles 1 and 2] Id: 311271000210108 Published date: Version: 0.0.23
UKALL14 with RITUximab and daSATinib [not for transplant] - Consolidation/delayed intensification [Cycle 3] Id: 311451000210101 Published date: Version: 0.0.7
UKALL14 with RITUximab and daSATinib [not for transplant] - Consolidation [Cycle 4] Id: 311291000210107 Published date: Version: 0.0.21
UKALL14 with RITUximab and daSATinib [not for transplant] - Maintenance Id: 311461000210103 Published date: Version: 0.0.20
311421000210105
1.0.0
15/01/2024
LEU ALL precursor B-cell - UKALL14 with RITUximab [40 years and under] [for transplant] Id: 391871000210108 Published date: Version: 1.0.0
Components ▾
Steroid pre-phase Id: 311231000210106 Published date: Version: 0.0.5
UKALL14 with RITUximab [40 years and under] [for transplant] - Phase 1 Induction Id: 391881000210105 Published date: Version: 0.0.7
UKALL14 with RITUximab [40 years and under] [for transplant] - Phase 2 Induction Id: 391771000210104 Published date: Version: 0.0.2
UKALL14 with RITUximab [40 years and under] [for transplant] - Intensification/CNS prophylaxis Id: 391891000210107 Published date: Version: 0.0.6
UKALL14 with RITUximab [40 years and under] [for transplant] - Consolidation [Cycles 1 and 2] Id: 391901000210108 Published date: Version: 0.0.5
UKALL14 with RITUximab [40 years and under] [for transplant] - Consolidation/delayed intensification [Cycle 3] Id: 391911000210105 Published date: Version: 0.0.9
UKALL14 with RITUximab [40 years and under] [for transplant] - Consolidation [Cycle 4] Id: 391811000210104 Published date: Version: 0.0.1
391871000210108
1.0.0
02/05/2024
LEU ALL precursor B-cell - UKALL14 with RITUximab [40 years and under] [not for transplant] Id: 392351000210100 Published date: Version: 1.0.0
Components ▾
Steroid pre-phase Id: 311231000210106 Published date: Version: 0.0.5
UKALL14 with RITUximab [40 years and under] [not for transplant] - Phase 1 Induction Id: 391881000210105 Published date: Version: 0.0.7
UKALL14 with RITUximab [40 years and under] [not for transplant] - Phase 2 Induction Id: 392361000210102 Published date: Version: 0.0.2
UKALL14 with RITUximab [40 years and under] [not for transplant] - Intensification/CNS prophylaxis Id: 392371000210108 Published date: Version: 0.0.12
UKALL14 with RITUximab [40 years and under] [not for transplant] - Consolidation [Cycles 1 and 2] Id: 391901000210108 Published date: Version: 0.0.5
UKALL14 with RITUximab [40 years and under] [not for transplant] - Consolidation/delayed intensification [Cycle 3] Id: 392381000210105 Published date: Version: 0.0.8
UKALL14 with RITUximab [40 years and under] [not for transplant] - Consolidation [Cycle 4] Id: 391811000210104 Published date: Version: 0.0.1
UKALL14 with RITUximab [40 years and under] [not for transplant] - Maintenance Id: 392391000210107 Published date: Version: 0.0.9
392351000210100
1.0.0
16/05/2024
LEU ALL precursor B-cell - UKALL14 with RITUximab [over 40 years] [for transplant] Id: 391751000210107 Published date: Version: 1.0.0
Components ▾
Steroid pre-phase Id: 311231000210106 Published date: Version: 0.0.5
UKALL14 with RITUximab [over 40 years] [for transplant] - Phase 1 Induction Id: 391761000210105 Published date: Version: 0.0.9
UKALL14 with RITUximab [over 40 years] [for transplant] - Phase 2 Induction Id: 391771000210104 Published date: Version: 0.0.2
UKALL14 with RITUximab [over 40 years] [for transplant] - Intensification/CNS prophylaxis Id: 391781000210102 Published date: Version: 0.0.2
UKALL14 with RITUximab [over 40 years] [for transplant] - Consolidation [Cycles 1 and 2] Id: 391791000210100 Published date: Version: 0.0.3
UKALL14 with RITUximab [over 40 years] [for transplant] - Consolidation/delayed intensification [Cycle 3] Id: 391801000210101 Published date: Version: 0.0.4
UKALL14 with RITUximab [over 40 years] [for transplant] - Consolidation [Cycle 4] Id: 391811000210104 Published date: Version: 0.0.1
391751000210107
1.0.0
02/05/2024
LEU ALL precursor B-cell - UKALL14 with RITUximab [over 40 years] [not for transplant] Id: 392401000210105 Published date: Version: 1.0.0
Components ▾
Steroid pre-phase Id: 311231000210106 Published date: Version: 0.0.5
UKALL14 with RITUximab [over 40 years] [not for transplant] - Phase 1 Induction Id: 391761000210105 Published date: Version: 0.0.9
UKALL14 with RITUximab [over 40 years] [not for transplant] - Phase 2 Induction Id: 392361000210102 Published date: Version: 0.0.2
UKALL14 with RITUximab [over 40 years] [not for transplant] - Intensification/CNS prophylaxis Id: 392411000210107 Published date: Version: 0.0.2
UKALL14 with RITUximab [over 40 years] [not for transplant] - Consolidation [Cycles 1 and 2] Id: 391791000210100 Published date: Version: 0.0.3
UKALL14 with RITUximab [over 40 years] [not for transplant] - Consolidation/delayed intensification [Cycle 3] Id: 392421000210102 Published date: Version: 0.0.3
UKALL14 with RITUximab [over 40 years] [not for transplant] - Consolidation [Cycle 4] Id: 391811000210104 Published date: Version: 0.0.1
UKALL14 with RITUximab [over 40 years] [not for transplant] - Maintenance Id: 392391000210107 Published date: Version: 0.0.9
392401000210105
1.0.0
16/05/2024
LEU ALL - UKALL14 [40 years and under] Id: 391821000210109 Published date: Version: 1.0.0
Components ▾
Steroid pre-phase Id: 311231000210106 Published date: Version: 0.0.5
UKALL14 [40 years and under] - Phase 1 Induction Id: 391831000210106 Published date: Version: 0.0.12
UKALL14 [40 years and under] - Phase 2 Induction Id: 312501000210108 Published date: Version: 0.0.8
UKALL14 [40 years and under] - Intensification/CNS prophylaxis Id: 391841000210103 Published date: Version: 0.0.31
UKALL14 [40 years and under] - Consolidation [Cycle 1] Id: 391851000210100 Published date: Version: 0.0.2
UKALL14 [40 years and under] - Consolidation [Cycle 2] Id: 312531000210103 Published date: Version: 0.0.8
UKALL14 [40 years and under] - Consolidation/delayed intensification [Cycle 3] Id: 391861000210102 Published date: Version: 0.0.1
UKALL14 [40 years and under] - Consolidation [Cycle 4] Id: 312551000210109 Published date: Version: 0.0.10
UKALL14 [40 years and under] - Maintenance Id: 312561000210107 Published date: Version: 0.0.12
391821000210109
1.0.0
02/05/2024
LEU ALL - UKALL14 [over 40 years] Id: 312481000210100 Published date: Version: 1.0.0
Components ▾
Steroid pre-phase Id: 311231000210106 Published date: Version: 0.0.5
UKALL14 [over 40 years] - Phase 1 Induction Id: 312491000210103 Published date: Version: 0.0.9
UKALL14 [over 40 years] - Phase 2 Induction Id: 312501000210108 Published date: Version: 0.0.8
UKALL14 [over 40 years] - Intensification/CNS prophylaxis Id: 312511000210105 Published date: Version: 0.0.4
UKALL14 [over 40 years] - Consolidation [Cycle 1] Id: 312521000210100 Published date: Version: 0.0.23
UKALL14 [over 40 years] - Consolidation [Cycle 2] Id: 312531000210103 Published date: Version: 0.0.8
UKALL14 [over 40 years] - Consolidation/delayed intensification [Cycle 3] Id: 312541000210106 Published date: Version: 0.0.23
UKALL14 [over 40 years] - Consolidation [Cycle 4] Id: 312551000210109 Published date: Version: 0.0.10
UKALL14 [over 40 years] - Maintenance Id: 312561000210107 Published date: Version: 0.0.12
312481000210100
1.0.0
23/04/2024

UKALL60+ Regimens

Published Sort regimens by
LEU ALL BCR-ABL1+ - UKALL60+ with daSATinib Id: 311031000210103 Published date: Version: 1.0.0
Components ▾
Steroid pre-phase [optional] Id: 310981000210107 Published date: Version: 0.0.3
UKALL60+ with daSATinib Phase 1 Induction Id: 311041000210106 Published date: Version: 0.0.13
UKALL60+ with daSATinib Phase 2 Induction Id: 311051000210109 Published date: Version: 0.0.6
UKALL60+ with daSATinib Consolidation Id: 311061000210107 Published date: Version: 0.0.8
UKALL60+ with daSATinib Maintenance Id: 311071000210101 Published date: Version: 0.0.19
311031000210103
1.0.0
09/11/2023
LEU ALL BCR-ABL1+ - UKALL60+ with imatinib Id: 310971000210105 Published date: Version: 1.0.0
Components ▾
Steroid pre-phase [optional] Id: 310981000210107 Published date: Version: 0.0.3
UKALL60+ with imatinib Phase 1 Induction Id: 310991000210109 Published date: Version: 0.0.13
UKALL60+ with imatinib Phase 2 Induction Id: 311001000210108 Published date: Version: 0.0.10
UKALL60+ with imatinib Consolidation Id: 311011000210105 Published date: Version: 0.0.8
UKALL60+ with imatinib Maintenance Id: 311021000210100 Published date: Version: 0.0.17
310971000210105
1.0.0
09/11/2023
LEU ALL - UKALL60+ [non-intensive] Id: 311081000210104 Published date: Version: 1.0.0
Components ▾
Steroid pre-phase Id: 310981000210107 Published date: Version: 0.0.3
UKALL60+ [non-intensive] Phase 1 Induction Id: 311091000210102 Published date: Version: 0.0.18
UKALL60+ [non-intensive] Phase 2 Induction Id: 311101000210109 Published date: Version: 0.0.3
UKALL60+ [non-intensive] Consolidation 1 Id: 311111000210106 Published date: Version: 0.0.9
UKALL60+ [non-intensive] Maintenance Id: 311121000210101 Published date: Version: 0.0.18
311081000210104
1.0.0
09/11/2023

Acute myeloid Regimens

Intensive Regimens

Published Sort regimens by
LEU AML - 7 + 3 IDA [IDArubicin and cytarabine] induction Id: 310951000210102 Published date: Version: 1.0.0
310951000210102
1.0.0
29/10/2023
LEU AML - ALFA 9801 [IDArubicin and cytarabine] induction Id: 264091000210107 Published date: Version: 1.0.0
264091000210107
1.0.0
28/03/2023
LEU AML - cytarabine 1.5 g/m2 [days 1,3,5] consolidation [courses 3 and 4] [60 years and over] Id: 60441000210108 Published date: Version: 2.0.0
60441000210108
2.0.0
29/10/2023
LEU AML - cytarabine 3 g/m2 [days 1,2,3] consolidation [courses 3 and 4] [under 60 years] Id: 60431000210100 Published date: Version: 3.0.0
60431000210100
3.0.0
29/10/2023
LEU AML - cytarabine 3 g/m2 [days 1,3,5] consolidation [courses 3 and 4] [under 60 years] Id: 60451000210106 Published date: Version: 2.0.0
60451000210106
2.0.0
29/10/2023
LEU AML - cytarabine 3 g/m2 [ONCE daily days 1 to 6] consolidation [courses 3 and 4] Id: 263841000210109 Published date: Version: 2.0.0
263841000210109
2.0.0
29/10/2023
LEU AML - DA 3+10 [DAUNOrubicin and cytarabine] induction [course 1] Id: 60461000210109 Published date: Version: 1.0.0
60461000210109
1.0.0
13/02/2023
LEU AML - DA[45] 3+7 [DAUNOrubicin and cytarabine] induction followed by high dose cytarabine consolidation [over 60 years] Id: 303631000210108 Published date: Version: 1.0.0
Components ▾
DA[45] 3+7 [DAUNOrubicin and cytarabine] induction [over 60 years] Id: 310931000210108 Published date: Version: 0.0.11
High dose cytarabine consolidation [over 60 years] Id: 310941000210100 Published date: Version: 0.0.14
303631000210108
1.0.0
29/10/2023
LEU AML - DA 3+8 [DAUNOrubicin and cytarabine] induction [course 2] Id: 60471000210103 Published date: Version: 2.0.0
60471000210103
2.0.0
29/10/2023
LEU AML - DA+GO-1 [DAUNOrubicin, cytarabine and Mylotarg [gemtuzumab ozogamicin]] induction [de novo CD33+] [good or intermediate risk] Id: 391691000210106 Published date: Version: 1.0.0
391691000210106
1.0.0
28/04/2024
LEU AML - DA+GO-2 [DAUNOrubicin, cytarabine and Mylotarg [gemtuzumab ozogamicin]] induction [de novo CD33+] [good or intermediate risk] Id: 310961000210104 Published date: Version: 1.0.0
310961000210104
1.0.0
29/10/2023
LEU AML - DAUNOrubicin, cytarabine and midostaurin induction, high dose cytarabine and midostaurin consolidation followed by midostaurin maintenance [FLT3 mutated] [60 years and over] Id: 303561000210103 Published date: Version: 1.0.0
Components ▾
DAUNOrubicin, cytarabine and midostaurin induction [60 years and over] Id: 303571000210109 Published date: Version: 0.0.14
High dose cytarabine and midostaurin consolidation [60 years and over] Id: 303581000210106 Published date: Version: 0.0.16
midostaurin maintenance Id: 303591000210108 Published date: Version: 0.0.15
303561000210103
1.0.0
29/10/2023
LEU AML - DAUNOrubicin, cytarabine and midostaurin induction, high dose cytarabine and midostaurin consolidation followed by midostaurin maintenance [FLT3 mutated] [under 60 years] Id: 303601000210103 Published date: Version: 1.0.0
Components ▾
DAUNOrubicin, cytarabine and midostaurin induction [under 60 years] Id: 303611000210101 Published date: Version: 0.0.15
High dose cytarabine and midostaurin consolidation [under 60 years] Id: 303621000210106 Published date: Version: 0.0.13
midostaurin maintenance Id: 303591000210108 Published date: Version: 0.0.15
303601000210103
1.0.0
29/10/2023
LEU AML - FLAG-Ida [fludarabine, cytarabine, filgrastim and IDArubicin] [60 years and over] Id: 60411000210107 Published date: Version: 1.0.0
60411000210107
1.0.0
19/09/2023
LEU AML - FLAG-Ida [fludarabine, cytarabine, filgrastim and IDArubicin] [under 60 years] Id: 60421000210102 Published date: Version: 1.0.0
60421000210102
1.0.0
19/09/2023
LEU AML FLT3-ITD mutated - soRAFENib maintenance after allogeneic stem cell transplant Id: 264121000210108 Published date: Version: 1.0.0
264121000210108
1.0.0
31/03/2023
LEU AML - MACE [amsacrine, cytarabine and etoposide] Id: 264081000210105 Published date: Version: 2.0.0
264081000210105
2.0.0
29/08/2023
LEU AML - Manchester Protocol [mitoxantrone and cytarabine IV] induction followed by consolidation Id: 303531000210107 Published date: Version: 1.0.0
Components ▾
Manchester Protocol [mitoxantrone and cytarabine IV] induction Id: 303541000210104 Published date: Version: 0.0.14
Manchester Protocol [mitoxantrone and cytarabine IV] consolidation Id: 303551000210101 Published date: Version: 0.0.17
303531000210107
1.0.0
29/10/2023
LEU AML - MidAC [mitoxantrone and cytarabine] Id: 264441000210105 Published date: Version: 2.0.0
264441000210105
2.0.0
29/08/2023
LEU AML Refractory - FLAG-Ida10 [fludarabine, cytarabine, filgrastim and IDArubicin] [under 60 years] Id: 264141000210102 Published date: Version: 1.0.0
264141000210102
1.0.0
19/09/2023

Non-intensive Regimens

Published Sort regimens by
LEU AML - azacitidine [7 day] Id: 264111000210103 Published date: Version: 1.0.0
264111000210103
1.0.0
31/03/2023
LEU AML - azacitidine and venetoclax Id: 264101000210100 Published date: Version: 1.0.0
264101000210100
1.0.0
28/03/2023
LEU AML - low dose cytarabine Id: 60491000210104 Published date: Version: 1.0.0
60491000210104
1.0.0
13/02/2023
LEU AML - low dose cytarabine and venetoclax Id: 60481000210101 Published date: Version: 1.0.0
60481000210101
1.0.0
13/02/2023

Relapsed Regimens

Published Sort regimens by
LEU AML FLT3-ITD mutated Relapsed - azacitidine and soRAFENib Id: 264131000210105 Published date: Version: 1.0.0
264131000210105
1.0.0
31/03/2023
LEU AML Relapsed - FLAG [fludarabine, cytarabine and filgrastim] [60 years and over] Id: 263981000210108 Published date: Version: 1.0.0
263981000210108
1.0.0
19/09/2023
LEU AML Relapsed - FLAG [fludarabine, cytarabine and filgrastim] [under 60 years] Id: 263861000210105 Published date: Version: 1.0.0
263861000210105
1.0.0
19/09/2023
LEU AML Relapsed - FLAG-amsacrine [fludarabine, cytarabine, filgrastim and amsacrine] [60 years and over] Id: 263871000210104 Published date: Version: 1.0.0
263871000210104
1.0.0
19/09/2023
LEU AML Relapsed - FLAG-amsacrine [fludarabine, cytarabine, filgrastim and amsacrine] [under 60 years] Id: 263881000210102 Published date: Version: 1.0.0
263881000210102
1.0.0
19/09/2023
LEU AML Relapsed - gilteritinib [FLT3 mutated] Id: 264151000210104 Published date: Version: 1.0.0
264151000210104
1.0.0
31/03/2023

Acute promyelocytic Regimens

Published Sort regimens by
LEU APL - AIDA induction and consolidations 1, 2 and 3 [70 years and under] Id: 311841000210102 Published date: Version: 1.0.0
Components ▾
AIDA [70 years and under] - Induction Id: 311851000210104 Published date: Version: 0.0.32
AIDA [70 years and under] - Consolidation 1 Id: 311861000210101 Published date: Version: 0.0.22
AIDA [70 years and under] - Consolidation 2 Id: 311871000210107 Published date: Version: 0.0.19
AIDA [70 years and under] - Consolidation 3 Id: 311881000210109 Published date: Version: 0.0.16
311841000210102
1.0.0
19/02/2024
LEU APL - AIDA induction and consolidations 1, 2 and 3 [over 70 years] Id: 391701000210106 Published date: Version: 1.0.0
Components ▾
AIDA [over 70 years] - Induction Id: 391711000210108 Published date: Version: 0.0.7
AIDA [over 70 years] - Consolidation 1 Id: 391721000210103 Published date: Version: 0.0.4
AIDA [over 70 years] - Consolidation 2 Id: 391731000210101 Published date: Version: 0.0.5
AIDA [over 70 years] - Consolidation 3 Id: 391741000210109 Published date: Version: 0.0.5
391701000210106
1.0.0
28/04/2024
LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [60 years and under] Id: 311551000210102 Published date: Version: 1.0.0
Components ▾
APML4 [60 years and under] - Induction Id: 311561000210104 Published date: Version: 0.0.27
APML4 [60 years and under] - Consolidation 1 Id: 311571000210105 Published date: Version: 0.0.22
APML4 [60 years and under] - Consolidation 2 Id: 311581000210107 Published date: Version: 0.0.27
APML4 [60 years and under] - Maintenance Id: 311591000210109 Published date: Version: 0.0.6
311551000210102
1.0.0
22/01/2024
LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [61 to 70 years] Id: 311761000210109 Published date: Version: 1.0.0
Components ▾
APML4 [61 to 70 years] - Induction Id: 311771000210103 Published date: Version: 0.0.4
APML4 [61 to 70 years] - Consolidation 1 Id: 311781000210101 Published date: Version: 0.0.5
APML4 [61 to 70 years] - Consolidation 2 Id: 311791000210104 Published date: Version: 0.0.7
APML4 [61 to 70 years] - Maintenance Id: 311801000210100 Published date: Version: 0.0.3
311761000210109
1.0.0
28/01/2024
LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [over 70 years] Id: 311701000210105 Published date: Version: 1.0.0
Components ▾
APML4 [over 70 years] - Induction Id: 311711000210107 Published date: Version: 0.0.3
APML4 [over 70 years] - Consolidation 1 Id: 311721000210102 Published date: Version: 0.0.3
APML4 [over 70 years] - Consolidation 2 Id: 311741000210108 Published date: Version: 0.0.6
APML4 [over 70 years] - Maintenance Id: 311751000210106 Published date: Version: 0.0.22
311701000210105
1.0.0
28/01/2024
LEU APL - arsenic trioxide and tretinoin induction followed by consolidation [AML17] Id: 311811000210103 Published date: Version: 1.0.0
Components ▾
arsenic trioxide and tretinoin [AML17] - Induction Id: 311821000210108 Published date: Version: 0.0.32
arsenic trioxide and tretinoin [AML17] - Consolidation Id: 311831000210105 Published date: Version: 0.0.23
311811000210103
1.0.0
28/01/2024
LEU APL - arsenic trioxide, tretinoin and prEDNISone induction followed by consolidation [standard risk] Id: 311601000210104 Published date: Version: 1.0.0
Components ▾
arsenic trioxide, tretinoin and prEDNISone [standard risk] - Induction Id: 311611000210102 Published date: Version: 0.0.22
arsenic trioxide and tretinoin [standard risk] - Consolidation Id: 311621000210107 Published date: Version: 0.0.21
311601000210104
1.0.0
22/01/2024
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [60 to 70 years] [high risk] Id: 312571000210101 Published date: Version: 1.0.0
Components ▾
Pethema LPA2005 [60 to 70 years] [high risk] - Induction Id: 312581000210104 Published date: Version: 0.0.8
Pethema LPA2005 [60 to 70 years] [high risk] - Consolidation 1 Id: 312591000210102 Published date: Version: 0.0.6
Pethema LPA2005 [60 to 70 years] [high risk] - Consolidation 2 Id: 312601000210107 Published date: Version: 0.0.6
Pethema LPA2005 [60 to 70 years] [high risk] - Consolidation 3 Id: 312611000210109 Published date: Version: 0.0.5
Pethema LPA2005 [60 to 70 years] [high risk] - Maintenance Id: 312621000210104 Published date: Version: 0.0.6
312571000210101
1.0.0
28/04/2024
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [70 years and under] [intermediate risk] Id: 311641000210101 Published date: Version: 2.0.0
Components ▾
Pethema LPA2005 [70 years and under] [intermediate risk] - Induction Id: 311651000210103 Published date: Version: 0.0.6
Pethema LPA2005 [70 years and under] [intermediate risk] - Consolidation 1 Id: 311661000210100 Published date: Version: 0.0.4
Pethema LPA2005 [70 years and under] [intermediate risk] - Consolidation 2 Id: 311671000210106 Published date: Version: 0.0.4
Pethema LPA2005 [70 years and under] [intermediate risk] - Consolidation 3 Id: 311681000210108 Published date: Version: 0.0.4
Pethema LPA2005 [70 years and under] [intermediate risk] - Maintenance Id: 311691000210105 Published date: Version: 0.0.4
311641000210101
2.0.0
28/04/2024
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [70 years and under] [low risk] Id: 391591000210105 Published date: Version: 1.0.0
Components ▾
Pethema LPA2005 [70 years and under] [low risk] - Induction Id: 391601000210100 Published date: Version: 0.0.7
Pethema LPA2005 [70 years and under] [low risk] - Consolidation 1 Id: 391621000210108 Published date: Version: 0.0.3
Pethema LPA2005 [70 years and under] [low risk] - Consolidation 2 Id: 391661000210101 Published date: Version: 0.0.4
Pethema LPA2005 [70 years and under] [low risk]- Consolidation 3 Id: 391671000210107 Published date: Version: 0.0.3
Pethema LPA2005 [70 years and under] [low risk] - Maintenance Id: 391681000210109 Published date: Version: 0.0.4
391591000210105
1.0.0
28/04/2024
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [high risk] Id: 391471000210105 Published date: Version: 1.0.0
Components ▾
Pethema LPA2005 [over 70 years] [high risk] - Induction Id: 391481000210107 Published date: Version: 0.0.7
Pethema LPA2005 [over 70 years] [high risk] - Consolidation 1 Id: 391491000210109 Published date: Version: 0.0.4
Pethema LPA2005 [over 70 years] [high risk] - Consolidation 2 Id: 391501000210104 Published date: Version: 0.0.6
Pethema LPA2005 [over 70 years] [high risk] - Consolidation 3 Id: 391511000210102 Published date: Version: 0.0.5
Pethema LPA2005 [over 70 years] [high risk] - Maintenance Id: 391521000210107 Published date: Version: 0.0.5
391471000210105
1.0.0
28/04/2024
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [intermediate risk] Id: 312701000210101 Published date: Version: 1.0.0
Components ▾
Pethema LPA2005 [over 70 years] [intermediate risk] - Induction Id: 312711000210104 Published date: Version: 0.0.7
Pethema LPA2005 [over 70 years] [intermediate risk] - Consolidation 1 Id: 312721000210109 Published date: Version: 0.0.4
Pethema LPA2005 [over 70 years] [intermediate risk] - Consolidation 2 Id: 312731000210106 Published date: Version: 0.0.5
Pethema LPA2005 [over 70 years] [intermediate risk] - Consolidation 3 Id: 312741000210103 Published date: Version: 0.0.3
Pethema LPA2005 [over 70 years] [intermediate risk] - Maintenance Id: 391411000210101 Published date: Version: 0.0.4
312701000210101
1.0.0
28/04/2024
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [low risk] Id: 391531000210109 Published date: Version: 1.0.0
Components ▾
Pethema LPA2005 [over 70 years] [low risk] - Induction Id: 391541000210101 Published date: Version: 0.0.6
Pethema LPA2005 [over 70 years] [low risk] - Consolidation 1 Id: 391551000210103 Published date: Version: 0.0.4
Pethema LPA2005 [over 70 years] [low risk] - Consolidation 2 Id: 391561000210100 Published date: Version: 0.0.4
Pethema LPA2005 [over 70 years] [low risk] - Consolidation 3 Id: 391571000210106 Published date: Version: 0.0.3
Pethema LPA2005 [over 70 years] [low risk] - Maintenance Id: 391581000210108 Published date: Version: 0.0.4
391531000210109
1.0.0
28/04/2024
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [under 60 years] [high risk] Id: 312631000210102 Published date: Version: 1.0.0
Components ▾
Pethema LPA2005 [under 60 years] [high risk] - Induction Id: 312651000210108 Published date: Version: 0.0.25
Pethema LPA2005 [under 60 years] [high risk] - Consolidation 1 Id: 312661000210106 Published date: Version: 0.0.18
Pethema LPA2005 [under 60 years] [high risk] - Consolidation 2 Id: 312671000210100 Published date: Version: 0.0.17
Pethema LPA2005 [under 60 years] [high risk] - Consolidation 3 Id: 312681000210103 Published date: Version: 0.0.16
Pethema LPA2005 [under 60 years] [high risk] - Maintenance Id: 312691000210101 Published date: Version: 0.0.20
312631000210102
1.0.0
28/04/2024

Chronic lymphocytic Regimens

Published Sort regimens by
LEU CLL - acalabrutinib Id: 264431000210102 Published date: Version: 1.0.0
264431000210102
1.0.0
19/09/2023
LEU CLL - chlorambucil Id: 60141000210100 Published date: Version: 1.0.0
60141000210100
1.0.0
15/12/2022
LEU CLL - chlorambucil [flat dosing] Id: 60131000210108 Published date: Version: 1.0.0
60131000210108
1.0.0
15/12/2022
LEU CLL - chlorambucil and oBINUTUZumab Id: 264411000210109 Published date: Version: 1.0.0
264411000210109
1.0.0
19/09/2023
LEU CLL - FCR [fludarabine, CYCLOPHOSPHamide and RITUximab] [oral] [3 day] Id: 264851000210105 Published date: Version: 1.0.0
264851000210105
1.0.0
21/07/2023
LEU CLL - FCR [fludarabine, CYCLOPHOSPHamide and RITUximab] [oral] [5 day] Id: 264841000210107 Published date: Version: 1.0.0
264841000210107
1.0.0
21/07/2023
LEU CLL - FCR [IV] fludarabine, CYCLOPHOSPHamide and RITUximab Id: 264831000210104 Published date: Version: 1.0.0
264831000210104
1.0.0
21/07/2023
LEU CLL - ibrutinib Id: 60151000210102 Published date: Version: 1.0.0
60151000210102
1.0.0
19/09/2023
LEU CLL - ibrutinib and venetoclax Id: 506821000210100 Published date: Version: 1.0.0
506821000210100
1.0.0
26/03/2026
LEU CLL Relapsed - aLEMTUzumab [IV] Id: 311301000210106 Published date: Version: 1.0.0
311301000210106
1.0.0
21/12/2023
LEU CLL Relapsed - aLEMTUzumab [subcut] Id: 311331000210101 Published date: Version: 1.0.0
311331000210101
1.0.0
24/12/2023
LEU CLL - RITUximab and bendamustine Id: 311311000210108 Published date: Version: 1.0.0
311311000210108
1.0.0
21/12/2023
LEU CLL - venetoclax Id: 264821000210101 Published date: Version: 1.0.0
264821000210101
1.0.0
21/07/2023
LEU CLL - venetoclax and oBINUTUZumab Id: 311321000210103 Published date: Version: 1.0.0
311321000210103
1.0.0
21/12/2023
LEU CLL - venetoclax and RITUximab Id: 311171000210102 Published date: Version: 1.0.0
311171000210102
1.0.0
30/11/2023
LEU CLL - zanubrutinib Id: 506781000210107 Published date: Version: 1.0.0
506781000210107
1.0.0
15/03/2026

Chronic myeloid Regimens

Published Sort regimens by
LEU CML - daSATinib Id: 264791000210105 Published date: Version: 1.0.0
Components ▾
daSATinib 100 Id: 264801000210109 Published date: Version: 0.0.8
daSATinib 140 Id: 264811000210106 Published date: Version: 0.0.13
264791000210105
1.0.0
21/07/2023
LEU CML - imatinib Id: 311141000210107 Published date: Version: 1.0.0
Components ▾
imatinib 400 Id: 311151000210105 Published date: Version: 0.0.11
imatinib 600 Id: 311161000210108 Published date: Version: 0.0.17
311141000210107
1.0.0
30/11/2023
LEU CML - nilotinib Id: 264381000210107 Published date: Version: 1.0.0
Components ▾
nilotinib 400 Id: 264391000210109 Published date: Version: 0.0.11
nilotinib 300 Id: 264401000210107 Published date: Version: 0.0.8
264381000210107
1.0.0
25/05/2023
LEU CML - pONATinib Id: 264941000210104 Published date: Version: 1.0.0
264941000210104
1.0.0
04/08/2023

Chronic myelomonocytic Regimens

Published Sort regimens by
LEU CMML - azacitidine [7 day] Id: 263851000210107 Published date: Version: 1.0.0
263851000210107
1.0.0
28/03/2023

Hairy cell Regimens

Published Sort regimens by
LEU HCL - cladribine Id: 264781000210108 Published date: Version: 2.0.0
264781000210108
2.0.0
26/03/2026
LEU HCL - cladribine and RITUximab Id: 311631000210109 Published date: Version: 2.0.0
311631000210109
2.0.0
26/03/2026
LEU HCL - RITUximab Id: 264881000210100 Published date: Version: 1.0.0
264881000210100
1.0.0
19/09/2023

Myelodysplastic syndrome Regimens

Published Sort regimens by
Myelodysplastic syndrome - azacitidine [5 day] Id: 263991000210105 Published date: Version: 1.0.0
263991000210105
1.0.0
28/03/2023
Myelodysplastic syndrome - azacitidine [7 day] Id: 264001000210101 Published date: Version: 1.0.0
264001000210101
1.0.0
28/03/2023

Myeloproliferative neoplasm Regimens

Published Sort regimens by
MPN - busulfan Id: 60241000210109 Published date: Version: 1.0.0
60241000210109
1.0.0
21/12/2022
MPN Myelofibrosis - ruxolitinib Id: 264891000210103 Published date: Version: 1.0.0
264891000210103
1.0.0
23/07/2023

T-cell prolymphocytic Regimens

Published Sort regimens by
LEU T-PLL - aLEMTUzumab [IV] Id: 264861000210108 Published date: Version: 2.0.0
264861000210108
2.0.0
24/12/2023
LEU T-PLL Relapsed - pentostatin Id: 264871000210102 Published date: Version: 1.0.0
264871000210102
1.0.0
23/07/2023